Table 4.
Selected clinical findings of Guillain Barré syndrome patients reported in VAERS following Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, October 2011 through July 2018.
| Case and Year |
Age (Yr) Sex |
Recent History of Illness |
Vaccines | Onset after Adenovirus vaccination (days) |
Diminished DTR |
CSF | EMG and NCS | Diagnosis | Treatment | Brighton level |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 2011 | 24M | URTI/sinusitis | Adeno Hep A Hep B MMR Varicella (5 days prior IPV IIV MCV4) | 31 | √ | 2 wbc normal protein | Consistent with AIDP/GBS | GBS | IVIG | 2 |
| 2 2011 OBS STUDY | 19-24M | URTI | Adeno (24 days prior MCV4 Tdap IIV Hep A) | 2 | √ | Normal | Consistent with GBS/AIDP | GBS | IVIG | 2 |
| 3 2011 OBS STUDY | ~22M | URTI (1-2 weeks prior to onset of weakness) | Adeno Hep A (5 days prior IIV Tdap MCV4 IPV) | 31 | √ | Normal | Consistent with AIDP/GBS | GBS | IVIG | 2 |
| 4 2012 | 18M | URTI | Adeno Hep A/Hep B MCV4 Tdap | 9 | √ | Not done | Consistent with AIDP/GBS | GBS | IVIG Prednisolone | 2 |
| 5 2012 | 27M | URTI (1 week prior to onset of weakness) | Adeno LAIV Tdap Hep A/Hep B MCV4 Varicella (35 days later Hep A/Hep B IPV Varicella) | 42 | √ | 1 wbc normal protein | No record | GBS | IVIG | 3 |
| 6 2012 | 20M | URTI/sinusitis (2 weeks prior to onset of weakness) | Adeno IIV IPV MCV4 Tdap (1 day prior Hep B MMR Varicella and 6 days later Hep A) | 32 | √ | 2 wbc elevated protein | Inflammatory neuropathy | GBS | IVIG | 1 |
| 7 2013 | 19F | None | Adeno Hep A/Hep B LAIV MCV4 Tdap | 9 | √ | 2483 rbc elevated protein (traumatic LP) | No record (discussed with neurology team) | GBS | IVIG | 3 |
| 8 2014 | 28F | None | Adeno Tdap MCV4 IIV | 19 | √ | 0 wbc normal protein | Mild sensory neuropathy | Atypical GBS | IVIG | 2 |
| 9 2014 | 25M | URTI | Adeno MCV4 Tdap | 25 | √ | 100 wbc† normal protein | AMSAN | GBS AMSAN | IVIG | 2 |
| 10 2015 | 17M | URTI | Adeno LAIV MMR Tdap MCV4 (4 days later Varicella) | 31 | √ | Not done | No record | GBS | IVIG | 3 |
| 11 2015 | 22M | Bell’s palsy treated with prednisolone and valacyclovir | Adeno Hep A LAIV Varicella Tdap MCV4 | 15 | Normal DTRs | 0 wbc elevated protein | Mild axonal involvement | GBS | IVIG | 1 |
| 12 2017 | 19M | Bell’s palsy treated with prednisolone | Adeno Tdap Varicella IPV Hep A/Hep B MCV4 IIV MMR | 27 | √ | Hemolyzed specimen | Not done | Miller Fisher syndrome | Steroid taper | 3 |
Abbreviations used in this table: Yr = year, DTR = deep tendon reflexes, CSF = cerebrospinal fluid, EMG and NCS = electromyogram and nerve conduction study, M = male, F = female, URTI = upper respiratory tract infection, Adeno = adenovirus vaccine, Hep A = hepatitis A vaccine, Hep B = hepatitis B vaccine, MMR = measles mumps and rubella vaccine, IPV = inactivated poliovirus vaccine, IIV = inactivated influenza vaccine, MCV4 = meningococcal conjugate vaccine, √ = diminished DTRs, wbc = white blood cell, AIDP = acute inflammatory demyelinating polyneuropathy, GBS = Guillain Barré syndrome, IVIG = intravenous immunoglobulin, OBS = patient included in observational study, Tdap = tetanus diphtheria attenuated pertussis vaccine, Hep A/Hep B = combined hepatitis A and B vaccine, LAIV = live attenuated influenza vaccine, LP = lumbar puncture, AMSAN = acute motor sensory axonal neuropathy.
Brighton criterion for cytoalbuminologic dissociation is CSF protein elevation above laboratory normal value and CSF total wbc count <50 cells/ul.